Our talented advisors assist the company on an as needed basis in activities ranging from trends in emerging scientific discoveries to best in class therapeutic treatments.
Senior Strategy and Business Advisors
Mr. Huateng Ma (“Pony” Ma), world renowned Chinese technology entrepreneur, is co-Founder, Chairman and CEO of Tencent Holdings Ltd. We are honored to include Mr. Pony Ma as one of our significant strategic shareholders as well as part of our Asia Business Council of Advisors. Pony’s success and perspectives advancing technology in China are very insightful to Athenex as we execute our medical technology strategy across both North America and China. Pony received his Bachelor of Science degree in Computer Science from Shenzhen University in 1993.
Antony Leung, former Financial Secretary of Hong Kong Special Administrative Region, is Group Chairman & CEO of Nan Fung Group in Hong Kong, a leading regional conglomerate focusing on property & investment businesses. He is also Independent Non-Executive Director of China Merchants Bank, Chairman of charity organizations Heifer International Hong Kong and Food Angel, and Chairman of Harvard Business School Association of Hong Kong.
Mr. Leung has had extensive experience in financial services, including Chairman of Greater China of Blackstone, Chairman of Asia of JP Morgan Chase, Asia Head of Citi Private Bank and Regional Head of Citi Investment Bank, Treasury and Greater China. In addition, he was independent director of Industrial and Commercial Bank of China, China Mobile (Hong Kong) Limited, American International Assurance (Hong Kong) Limited, and international advisory board member of China Development Bank. His past public service includes Non-Official Member of the Executive Council, member of the Exchange Fund Advisory Committee, Hong Kong Airport Authority, Chairman of the Education Commission and University Grants Committee in Hong Kong.
Mr. Leung graduated from the University of Hong Kong in 1973, and attended Harvard Business School’s Program for Management Development and Advanced Management Program.
Dr. Hsia is a co-founder of Watson Pharmaceuticals, a publicly traded company listed in New York Stock Exchange (ticker: WPI). He was formerly Senior Vice President of Scientific Affairs of Watson Pharmaceuticals before his retirement. Dr. Hsia was formerly on the Athenex board before he retired in 2011. A veteran of the pharmaceutical industry, Dr. Hsia was involved in the development of multiple pharmaceutical formulations for over twenty years. Dr. Hsia received a PhD in Industrial and Physical Pharmacy from Purdue University.
Mr. Collin Lau is the founder of BEI Capital, an Asian-based global real estate and alternative investment company. Collin was previously a managing director, head of global real estate and head of European private equity at China Investment Corporation. With 29 years of corporate, financial and investment management experience, Collin was previously a managing director at Starr International, where he was responsible for its private equity and real estate investments in Asia Pacific, and a managing director at Baring Private Equity Asia. Collin holds a Master of Laws degree with distinction in Corporate and Financial Law from the University of Hong Kong. In 2010 he was named the Asia Industry Figure of the Year by PERE, and listed as one of the top 50 industry figures by Estate Gazette UK. In 2015 he was ranked 25th of the top 100 most influential global industry figures by PERE for the last decade (2005-2015).
Clinical Scientific Advisory Board Consultants
Dr. Weitman is a Professor of Pediatrics and Director of the Institute for Drug Development at the Cancer Therapy and Research Center in San Antonio, Texas, with a joint appointment in Pharmacology and Medicine. He earned his BS in Microbiology from the University of Wisconsin-LaCrosse, LaCrosse, WI; and his MS in Pharmacology, PhD in Pharmacology and his MD in Medicine from the Medical College of Wisconsin, Milwaukee, WI. Dr. Weitman performed his Postgraduate internship and residency in pediatrics at the University of Texas Southwestern Medical Center, Dallas, TX; and his fellowship in pediatric hematology/oncology from the University of Texas Southwestern Medical Center, Dallas, TX. Dr. Weitman is Board certified in pediatrics and pediatric hematology-oncology. Dr. Weitman is an inventor on numerous patents and author of over 200 papers, abstracts and chapters in medical literature.
Dr. Von Hoff is a highly regarded medical oncologist and drug developer, serving in the role of Physician-in-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen), Professor of Medicine at the Mayo Clinic, Chief Scientific Officer of the HonorHealth Research Institute, and Medical Director of Research as well as Chief Scientific Officer at US Oncology. Dr. Von Hoff and his team are focused on the development of new anticancer agents and the development of new treatments for patients. Dr. Von Hoff has been the founder and/or editor of numerous scientific publications including Molecular Cancer Therapeutics and Clinical Cancer Research. He was also a founder of ILEX TM Oncology, a company that had two anti-cancer agents approved by the FDA, Campath and Clolar. In addition, he has been on both the AACR and American Society of Clinical Oncology Board of Directors, is a past president of the American Association for Cancer Research, is a fellow of the American College of Physicians and was a member of President Bush’s National Cancer Advisory Board from 2004 to 2010.
Dr. Benet, Professor and former Chairman (1978-1998), Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California, San Francisco, received his AB (English), BS (Pharmacy), MS from the University of Michigan and PhD from the University of California. He has received eight honorary doctorates: Uppsala University, Sweden (PharmD, 1987), Leiden University, The Netherlands (PhD, 1995), University of Illinois at Chicago (DSc, 1997), Philadelphia College of Pharmacy and Science (DSc, 1997), Long Island University (DSc, 1999), University of Athens, Greece (PhD, 2005), Catholic University of Leuven, Belgium (PhD, 2010) and University of Michigan (DSc, 2011). His research interests, more than 530 publications, 6 books and 11 patents are in the areas of pharmacokinetics, biopharmaceutics, drug delivery and pharmacodynamics. Dr. Benet is listed by Thompson Reuters as one of the most highly cited pharmacologists worldwide, with his published peer-reviewed papers cited more than 20,000 times.
Dr. C. Tak Hung is the Managing Director and owner of Zenith Technology Corporation Ltd. in Dunedin, New Zealand. He received his degrees in Aberdeen, Scotland. Before establishing Zenith Technology in 1987, he was a senior lecturer in the Pharmacy Department, University of Otago from 1983 to 1987. He has published over 80 research articles and has three patents.
Dr. Ma is an Associate Professor of Oncology in the Department of Medicine at Roswell Park Cancer Institute. Dr. Ma’s areas of expertise include colon cancer, liver cancer, pancreatic cancer and rectal cancer; and his special interests include drug development and Phase I clinical trials (advanced solid tumors). Dr. Ma received his MBBS from the University of Sydney, Sydney, NSW, Australia, and spent his fellowship in Medical Oncology/Hematology at Johns Hopkins University, Baltimore MD. Dr. Ma’s Board Certifications are in Hematology, American Board of Internal Medicine; Internal Medicine, American Board of Internal Medicine and Medical Oncology, American Board of Internal Medicine.
Dr. Williams is President of Williams Cancer Drug Consulting and he is a board certified medical oncologist with 16 years of oncology review experience at FDA and 3 years of experience in oncology clinical development in the pharmaceutical industry. As a consultant, he provides a unique blend of experience in oncology clinical trial design and in oncology drug regulation. He is inventor on numerous patents and author of over 200 papers, abstracts and chapters in medical literature. Dr. Williams’ areas of special expertise include protocol design for regulatory success, oncology regulatory meetings, scientific review of protocols and he is an Independent Data Monitoring Committee member. Dr. Williams earned his MD from the University of Alabama School of Medicine and he is boarded in both internal medicine and medical oncology.
Advisors to the CEO
Lewis Ho is recognized as one of the leading IP and transactional attorneys in Asia focusing in the life sciences sector. He helps pharmaceutical and biotechnology companies and their financial sponsors to capture, manage, risk assess, evaluate and monetize their intellectual property assets.
Lewis has extensive experience advising on both inbound and outbound transactions, and he has negotiated more than 120 M&A, collaboration, outsourcing, joint venture, licensing and financing (including IPO) deals.
He spearheaded the establishment of the GSK R&D Centre in Shanghai, one of the first and largest projects of its kind in China.
Dr. Kejian Zhang, Professor of School of Pharmaceutical Sciences of Sun Yat-sen University, Chief Scientist of South China Center for Innovative Pharmaceuticals, has over 30 years of experience in pharmaceutical R&D and administration of drug registration in China. He graduated from China Medical University (Shenyang, China), and received a PhD from School of Pharmaceutical Sciences of Chiba University (Chiba, Japan).
Dr. Zhang has been involved in pharmacology, toxicology and pharmacokinetic research at the Institute of Materia Medica Chinese Academy of Medical Science. He has also conducted collaborative research in the National Institute of Science and Technology of Korea and University Hospital of Zurich, Switzerland.
Dr. Zhang served as deputy director of the Center for Drug Evaluation and later deputy director of the Center for Medical Device Evaluation under the National Medical Products Administration (PRC), for over a decade. He has extensive experience in the technical review of new drugs and has participated in the drafting and revision of many technical guidelines and regulations for the development of new drugs and biological products.
Emeritus Science Advisors
Dr. Barnett is a successful drug development executive who brought four drugs, two of which are blockbusters, to the marketplace during his tenure at Schering-Plough (SP). He led the effort that resulted in the discovery of Claritin (and Clarinex), a non-sedating antihistamine that is Schering-Plough’s leading product and was the fifth leading drug, based on sales, in the world. He also managed the discovery program that led to Zetia, a novel cholesterol-lowering agent that was introduced to the market in November 2002. In 1994, Dr. Barnett assumed the duties of Vice President of Technology Acquisition and External Collaborations and was involved with the in-licensing of new technology and the structuring of academic collaborations for SP. Collaborations included Cephalon, Pharmacopeia, Neurogen, Genome Therapeutics, Human Genome Sciences, Chiroscience, Synteni/Incyte, Navicyte, Terragen, Biosearch Italia, Transgene, Myriad Genetics and Genzyme. Significant academic collaborations included The Whitehead Institute, Duke University, Stanford University, University of Toronto, Harvard University, Aaron Diamond Research Center, Vanderbilt University, Columbia University, Penn State University, SUNY at Buffalo and N.Y.U. Dr. Barnett elected to retire from SP in 1998 and continued to provide consulting services to SPRI and other companies as a consultant until assuming his current role with Kinex Pharmaceuticals.
Dr. Barnett received a Ph.D. in pharmacology from the University at Buffalo (UB), School of Medicine and is active on an advisory board for the School of Pharmacy at UB.
David, one of the original founders of the Company, is a leader in the field of structure based drug design. Following doctoral studies in chemistry at the University at Buffalo, he spent ten years at Merck Sharp and Dohme Research Laboratories, where he directed a variety of drug discovery projects. In 1989, he returned to academia and joined the chemistry faculty at SUNY at Buffalo, where he has had a productive career that has focused on developing protein kinase inhibitors.
David’s expertise has been sought by pharmaceutical and biotechnology companies worldwide, including: Lederle/Wyeth-Ayerst Research Laboratories; New Medical Technologies; Sphinx/Eli Lilly Pharmaceuticals Inc.; Yuhan Corporation; Periodontix, Inc.; ICAgen, Inc.; ARPIDA, Scientific Advisory Board & Founding Scientist; and Signal Pharmaceuticals, Inc. Most notably, he led the chemistry effort at Hypnion, Inc., which was sold to Eli Lilly in 2009 for more than $300 million. The company’s major asset was an insomnia drug that was designed and discovered under the leadership of David.
Dr. Lam, a key leader in the field of ophthalmology in the Asia-Pacific Region and beyond, has been serving as Deputy of the National People’s Congress of China since 2008. He holds leadership positions in numerous ophthalmology organizations, including President of the Asia-Pacific Academy of Ophthalmology and Editor-in-Chief of the Asia-Pacific Journal of Ophthalmology, among others. In addition to his current role as the Head of the C-MER Dennis Lam Eye Center (HK) & Hospital (Shenzhen), Dr. Lam previously was the Chairman of the eye department of The Chinese University of Hong Kong (1998-2011) and the World Ophthalmology Congress (2008). Dr. Lam has received many prestigious awards, including, among others, the Top 100 Most Influential Ophthalmologists in the World (2014), the Best Clinical Teacher in the Asia-Pacific Region(2011) and Ten Outstanding Young Persons of the World (1995).
Dr. Gelman is the John and Santa Palisano Chair of Cancer Genetics at Roswell Park Cancer Institute, as well as RPCI Comprehensive Cancer Center Genetics Program Leader, Chair of the RPCI Cell and Molecular Biology Academic Department of SUNY at Buffalo, a Professor of Oncology and the Director of the Genomics and shRNA Core Resource Labs at RPCI. He received his BA from Wesleyan University, MA, MPh and PhD degrees in Microbiology from Columbia University and was a Postdoctoral Associate in the laboratory of Dr. Hidesaburo Hanafusa at The Rockefeller University. After 13 years as an Assistant and Associate Professor in Microbiology and Infectious Diseases at Mount Sinai School of Medicine, Dr. Gelman came to RPCI in 2003. His research has focused on the roles of Src family kinases in promoting oncogenic progression, especially in relation to metastasis formation. His lab has expertise in identifying metastasis suppressor and inducer genes using genetic screens, dissecting Src/FAK-regulated pathways in oncogenesis, mouse models of the role of Src in castration recurrent prostate cancer, identification of Src-regulated androgen receptor gene expression signatures that drive prostate cancer malignancy. In conjunction with Athenex, LLC, he has participated in the characterization of small molecule inhibitors of Src in preventing or treating recurrent/metastatic cancer in preclinical models. Dr. Gelman has been a member on multiple NIH and DoD grant study sections and integration panels, and is currently an Associate Editor of Cancer Research.
Dr. Qu is an Associate Professor in the Pharmaceutical Sciences Department of SUNY-Buffalo. His interests are in Proteomics and Pharmaceutical Analysis and their applications in pharmaceutical and clinical research. His research programs in the proteomic field involve: i) High-resolution and large-scale expression profiling of pathological proteomes (e.g. for cardiovascular diseases, colon cancer and infectious diseases, HIV, COPD, etc.) for the discovery of disease/drug-effect biomarkers by gel-free LC/MS methods; ii) Sensitive identification, localization and quantification of post-translational modifications in complex proteomes, with the emphases on arginine methylation and phosphorylation. Novel anti-PTM-peptides capture procedure and alternating collision induced dissociation (CID)/electron transferring dissociation (ETD) are employed to obtain abundant PTM information; iii) Targeted quantification of protein drugs and biomarkers for clinical study. Dr. Qu’s lab possesses many state-of-the-art LC/MS instruments, including a high resolution/accuracy LTQ/Orbitrap ELITE with ETD, a highly sensitive TSQ Quantum Ultra EMR triple-quadrupole instrument, ultra-high pressure nano-LC systems, and HPLC instruments for pre-fraction and ion chromatography. A number of key analytical advances have been developed by his lab that greatly enhanced drug discovery and development processes. He has been actively collaborating with Athenex since 2010 using cutting-edge proteomics and LC/MS techniques for in-depth investigation of the mechanisms of actions of Athenex compounds.
Professor Luo has been a Professor in the Department of Chemistry in TsingHua University in China since 1994. He is also the Director of the Network Center (Ministry of Education) for Collaborative Study of TCM Modernization in TsingHua University. Previously, he was Deputy Director of Analytical Center, Assistant Dean of Institute of Life Science and Engineering, Deputy Director of Institute of Pharmacy and Director of Modern Research Center of Traditional Research Medicine. During 2007 to 2012, he set up the College of Pharmaceutical Sciences, Nanki University in Tianjin and also served as the Executive Dean of College of Pharmaceutical Sciences during this period. Professor Luo has published more than 700 scientific papers and was also inventor or co-inventor in 25 issued patents. He has won numerous awards including National Award of Science and Technology Advancement and a number of Ministerial Awards of Science and Technology Advancement. He is Chairman of Chinese Biopharmaceutical Technology Association (CBPTA), Associate Editor-in-Chief of Pharmacopoeia of PR China and also member of the National New Drug Approval Council of China.
Dr. Davis is a consultant in nonclinical pharmaceutical development, with emphasis on toxicology and pathology. He received his DVM and Ph.D. in Veterinary Pathology from Cornell University and is a Diplomat of the American College of Veterinary Pathologists. He was previously Director of Toxicology at Schering-Plough Corp (now Merck), where he directed the nonclinical programs leading to worldwide marketing approval for many drugs, including biologics and small molecules. Since 2004, he has been President and Director of Toxicology Consultation at PreclinPharma, advising on the design and management of nonclinical programs in pharmaceutical development.
CMC, Clinical Research and Regulatory Affairs
Dr. Fang is a consultant in Clinical Operations and Regulatory Affairs with more than 15 years of experience in the pharmaceutical industry. Prior to that, she was on the faculty in Pediatric Gastroenterology, Hepatology and Nutrition at the University of Florida. After entering the pharmaceutical industry, she served as the project lead in the successful application of PEG-Intron for the treatment of chronic hepatitis C in the US and EU and subsequently took on positions as Head of Clinical Development and Regulatory Affairs for a number of pharmaceutical and biotechnology companies. Dr. Fang was instrumental in the filing of numerous INDs, liaising with health authorities, planning of clinical programs and overseeing clinical trials from Phase 1 to Phase 3.
Mr. Johnson Chan is a Managing Director or Key Step Capital Limited, an investment holding company and business consultancy focused on various industries and across the capital structure. Johnson has over twenty years of investment banking and investment experience. Prior to Key Step Capital he was Head of Financing, Greater China for Deutsche Bank, a Managing Director of SSG Capital Management, a special situations fund and in Lehman Brothers Asia Special Situations as Senior Vice President and Morgan Stanley’s Fixed Income Division as Head of Hong Kong Fixed Income.
Mr. Gallagher is an accomplished Capital Markets Executive, Advisor and Investor with a distinguished record of success in both the public and private markets. He has nearly 20 years of experience on Wall Street and extensive expertise in alternative investments, research and marketing. He is a founding partner and was CEO of BDR Research Group, LLC, a healthcare focused institutional research boutique specialized in providing services for clients in the healthcare investing, financing and operations areas. Prior, Mr. Gallagher worked for investment and research firms Kidder Peabody, PaineWebber and New Vernon Associates.
Mr. Suh has nearly 30 years of corporate experience, 20 years in the US and 10 years in Seoul, South Korea. He has worked at Bell Labs, Fannie Mae and the World Bank in technology, strategy, organizational change and international development arenas. He has coached the World Bank Pakistan, Philippines and Peru project teams. He has seven years of project management leadership experience as a volunteer leader at Project Management Institute. Mr. Suh has taught project management, cross-cultural communication, negotiation, conflict management, merger harmonization, creativity and leadership at universities and multinational corporations such as Samsung and LG. He has coached executives for the past 14 years. He serves as an advisor to Korean and international companies.